INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026

Stock News05-11

INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual results, revenue for 2025 reached RMB 132 million, with a loss of RMB 341 million. Notably, the lock-up period for INNOGEN-B's cornerstone investors is set to expire on May 14, 2026, with the related shares officially becoming tradable on May 15. The cornerstone investors collectively hold 4.201 million shares. A research report from Guohai Securities stated that the Suba T2D indication received NMPA certification in January 2025 and has been included in the National Reimbursement Drug List. Phase III weight loss data for Suba is expected to be released by the end of 2026. The report noted that in the Phase IIb study, the 20 mg once-weekly dosing regimen achieved a 10.6% weight reduction at week 18, with no plateau observed at that time point, while the 20 mg once-every-two-weeks regimen achieved a 9.7% weight reduction at week 18. Patient enrollment for the Phase III clinical study targeting obesity and overweight was completed in 2025. Topline data from this trial is anticipated to be announced by the end of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160489079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-11 11:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160489079","market":"sh","top_or_hot":-1,"title":"INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026","media":"Stock News","content":"<p>INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual results, revenue for 2025 reached RMB 132 million, with a loss of RMB 341 million. Notably, the lock-up period for INNOGEN-B's cornerstone investors is set to expire on May 14, 2026, with the related shares officially becoming tradable on May 15. The cornerstone investors collectively hold 4.201 million shares. A research report from Guohai Securities stated that the Suba T2D indication received NMPA certification in January 2025 and has been included in the National Reimbursement Drug List. Phase III weight loss data for Suba is expected to be released by the end of 2026. The report noted that in the Phase IIb study, the 20 mg once-weekly dosing regimen achieved a 10.6% weight reduction at week 18, with no plateau observed at that time point, while the 20 mg once-every-two-weeks regimen achieved a 9.7% weight reduction at week 18. Patient enrollment for the Phase III clinical study targeting obesity and overweight was completed in 2025. Topline data from this trial is anticipated to be announced by the end of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B Shares Surge Over 43% in Morning Trading; Phase III Weight Loss Data for Suba Anticipated by End-2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-11 11:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual results, revenue for 2025 reached RMB 132 million, with a loss of RMB 341 million. Notably, the lock-up period for INNOGEN-B's cornerstone investors is set to expire on May 14, 2026, with the related shares officially becoming tradable on May 15. The cornerstone investors collectively hold 4.201 million shares. A research report from Guohai Securities stated that the Suba T2D indication received NMPA certification in January 2025 and has been included in the National Reimbursement Drug List. Phase III weight loss data for Suba is expected to be released by the end of 2026. The report noted that in the Phase IIb study, the 20 mg once-weekly dosing regimen achieved a 10.6% weight reduction at week 18, with no plateau observed at that time point, while the 20 mg once-every-two-weeks regimen achieved a 9.7% weight reduction at week 18. Patient enrollment for the Phase III clinical study targeting obesity and overweight was completed in 2025. Topline data from this trial is anticipated to be announced by the end of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1160489079","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160489079","pubTimestamp":1778470951,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","III":"信息服务","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard","02591":"银诺医药-B","BK4134":"信息科技咨询与其它服务","BK4588":"碎股"},"translate_title":"INNOGEN-B股价早盘飙升逾43%；Suba的III期减肥数据预计将于2026年底公布","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1,"VXUS":1,"III":1},"content_text":"INNOGEN-B (02591) rose over 43% in morning trading. As of the time of writing, the stock was up 42.21%, trading at HK$17.99 with a turnover of HK$173 million. According to the company's annual results, revenue for 2025 reached RMB 132 million, with a loss of RMB 341 million. Notably, the lock-up period for INNOGEN-B's cornerstone investors is set to expire on May 14, 2026, with the related shares officially becoming tradable on May 15. The cornerstone investors collectively hold 4.201 million shares. A research report from Guohai Securities stated that the Suba T2D indication received NMPA certification in January 2025 and has been included in the National Reimbursement Drug List. Phase III weight loss data for Suba is expected to be released by the end of 2026. The report noted that in the Phase IIb study, the 20 mg once-weekly dosing regimen achieved a 10.6% weight reduction at week 18, with no plateau observed at that time point, while the 20 mg once-every-two-weeks regimen achieved a 9.7% weight reduction at week 18. Patient enrollment for the Phase III clinical study targeting obesity and overweight was completed in 2025. Topline data from this trial is anticipated to be announced by the end of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160489079","isCrawlerRequest":true}